The central PANCAIM concept is to integrates the whole spectrum of genomics with radiomics and pathomics, to improve personalized medicine of pancreatic cancer. PANCAIM’s concept is unique as it integrates, for the first time, these three modalities with AI, using an explainable, data-efficient, twostaged AI approach. AI biomarkers transform the unimodal data domains into interpretable likelihoods of intermediate disease features. A second AI layer merges the biomarkers and responds with an integrated assessment of prognosis, prediction and monitoring of therapy response, to assist in clinical decision making.
PANCAIM builds on four key concepts of AI in Healthcare: data providers, clinical expertise, AI developers, and MedTech companies to connect to data and bring AI to healthcare. Data quantity and quality is the main factor for successful AI. Partners provide eleven Pan European repositories of almost 6000 patients that are open to ongoing accrual.
More info: https://pancaim.eu/
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101016851, project PANCAIM.